

Press release

In partnership with Gustave Roussy, HyperCube Institute researchers discover a gene expression signature predictive of 3 year survival in early stage lung cancer

Paris, April 3rd 2014 – As part of a research project conducted in partnership with Gustave Roussy , European Comprehensive Cancer Center , researchers from HyperCube Institute, a philanthropic non-profit organization which benefits, thanks to its sponsor BearingPoint, from HyperCube® data analysis technology, have identified a gene expression signature predictive of 3-year survival in early stage lung cancer (non metastatic lung adenocarcinoma).

The results of this research will be presented during the poster session at the Cellular and Molecular Biology session at AACR (American Association for Cancer Research), a leading global conference in cancer research, to be held in San Diego from 5 to 9 April 2014.

This scientific breakthrough was made possible by HyperCube®, a data analysis technology able to extract from complex databases the combinations of factors driving the studied phenomena. It is also the result of a collaboration between Gustave Roussy's cancer research specialists and HyperCube Institute mathematicians and data scientists.

These results allow to contemplate to deliver to clinicians high performing molecular diagnostics tools enabling to identify patients at high risk of relapse after tumor surgical resection, and to propose them an appropriate preventive treatment.

The collaboration between the HyperCube Institute and Gustave Roussy continues with two objectives: to improve the predictive performance of the model, maximize its clinical interest, and to extend this research to other types of lung cancer (particularly squamous cell cancer , or "smoker's cancer").

Professor Jean-Charles Soria, Head of the Department of Therapeutic Innovations and Early Trials at Gustave Roussy, and an internationally recognized lung cancer expert, said: "With its innovative mathematical methodology, HyperCube® technology allows us to identify new signals in existing databases."

François d'Ormesson , Director of the HyperCube Institute, said: "We are delighted and proud of these first results that demonstrate the value of the HyperCube® technology for complex data analysis in biomedical research. They demonstrate our commitment and the commitment of BearingPoint to healthcare research through partnerships with prestigious academic teams such as Gustave Roussy."

About HyperCube® technology

The HyperCube® technology is an innovative mathematical approach to the analysis of complex data. Fruit of many years of research, it is used in many business areas including marketing and customer relations management, fraud detection, optimization of complex industrial processes, and healthcare. It was acquired by BearingPoint in 2011.

About the HyperCube Institute

The HyperCube Institute is an endowment fund which mission is to facilitate the use of HyperCube® technology for research on rare and orphan diseases, and major public health issues. BearingPoint is its main sponsor. The HyperCube Institute conducts research projects in partnership with prestigious institutions, including Gustave Roussy and the EORTC for cancer and Pasteur Institute for Infectious Diseases.

Contact Institut HyperCube : François d'Ormesson (contact@institut-hypercube.org)

About BearingPoint

BearingPoint consultants understand that the world of business changes constantly and that the resulting complexities demand intelligent and adaptive solutions. Our clients, whether in commercial or financial industries or in government, experience real results when they work with us. We combine industry, operational and technology skills with relevant proprietary and other assets in order to tailor solutions for each client's individual challenges. This adaptive approach is at the heart of our culture and has led to long-standing relationships with many of the world's leading companies and organizations. Our global consulting network of 8600 people serves clients in more than 70 countries and engages with them for measurable results and long-lasting success.

For more information, please visit: www.bearingpoint.com

About Gustave Roussy

Europe's leading oncology centre, Gustave Roussy is an international institute with expertise in oncology entirely dedicated to its patients. Its single venue contains 2,600 health professionals whose three main missions are care-giving, research and education. By devoting nearly 20% of its budget to research, Gustave Roussy proudly declares its determination to promote research as an innovative engine for the benefit of its patients – www.gustaveroussy.fr

Press Contacts

BearingPoint France

Sandrine Pigot,
Marketing & Communication Manager
+33 6 23 50 16 63
sandrine.pigot@bearingpoint.com

LEWIS PR

Lucie Robet – Mathilde Lakhdar
+33 1 55 31 75 63
bearingpoint@lewispr.com

Gustave Roussy

Christine Lascombe
Direction de la communication
+33 1 42 11 41 75
christine.lascombe@gustaveroussy.fr

Medial

Claire Parisel
+33 1 53 83 81 52
claireparisel@medial-rp.com